Oncology

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxolitinib is the small molecule JAK1/2 inhibitor found in Jakafi, for myelofibrosis treatment of Incyte. Incyte has placed itself to produce more cash from the molecule by positioning it as an atopic dermatitis treatment option for patients. Lately, Incyte has shown top-line data from the second phase 3 trial. The second trial also hit its primary endpoint, wit...